基于MRI与临床参数预测肝细胞癌微波消融后侵袭性复发的风险模型
本回顾性研究纳入393例单发≤3 cm肝细胞癌患者,术前行增强MRI并接受微波消融,构建ARMA评分模型预测侵袭性复发。独立预测因素为肿瘤邻近门脉区、消融时长及MRI动脉期高强化比例,模型C-index为0.72,优于其他分期系统与已知危险因素。
要点
- 肿瘤邻近门脉区、消融时长及MRI动脉期高强化比例是侵袭性复发的独立预测因素。
- ARMA评分≥0.700的高危患者无侵袭性复发生存期与无复发生存期均更差。
- ARMA模型C-index为0.72,优于对照分期系统与已知危险因素的0.58-0.63。
核心结论
- 整合肿瘤邻近门脉区、消融时长及动脉期高强化比例的ARMA评分可预测无侵袭性复发生存期并识别侵袭性复发高危患者。
研究设计与样本
- 回顾性研究,纳入2014年6月至2019年10月连续单发≤3 cm肝细胞癌患者393例,术前行增强MRI并接受微波消融;训练集275例,测试集118例,采用多变量Cox回归构建模型并以C-index评估。
关键影像表现/征象
- 肿瘤邻近门脉区与无侵袭性复发生存期独立相关(HR 1.72,P < .001)。
- 消融时长与无侵袭性复发生存期独立相关(HR 1.00,P = .02)。
- MRI动脉期高强化比例与无侵袭性复发生存期独立相关(HR 1.77,P = .002)。
诊断标准与关键数值
- 训练集侵袭性复发79/275例(28.7%),测试集37/118例(31.4%)。
- ARMA模型预测无侵袭性复发生存期的C-index为0.72,对照分期系统与已知危险因素为0.58-0.63(P值范围<.001-.003)。
- ARMA评分≥0.700为高危组,<0.700为低危组;高危组无侵袭性复发生存期(P < .001)与无复发生存期(P = .002)均更低。
临床应用与阅片要点
- 术前MRI评估需关注肿瘤是否邻近门脉区及动脉期高强化比例,并结合消融时长计算ARMA评分。
- ARMA评分≥0.700可识别侵袭性复发高危患者,其无侵袭性复发生存期与无复发生存期更差。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To develop and validate a risk score model for predicting aggressive recurrence (AR) of hepatocellular carcinoma (HCC) after microwave ablation (MWA). Materials and Methods This retrospective study included consecutive patients with solitary HCC (≤3 cm) who underwent preoperative contrast-enhanced MRI and MWA from June 2014 to October 2019. In the training set, multivariable Cox regression analysis identified clinical, laboratory, and MWA parameters and MRI features associated with AR. The resulting predictive model, named Aggressive Recurrence after Microwave Ablation (ARMA), was evaluated in the test set using the concordance index (C-index) and compared with the Barcelona Clinic Liver Cancer staging system and known risk factors. Kaplan-Meier survival curves were compared using the log-rank test. Results A total of 393 eligible patients (mean age, 57.7 years ± 11.2 [SD]; 299 [76.1%] male) were included. AR occurred in 79 of 275 (28.7%) patients in the training set and 37 of 118 (31.4%) patients in the test set. Independent predictors of AR-free survival (ARFS) were periportal location (hazard ratio [HR], 1.72; P < .001), ablation duration (HR, 1.00; P = .02), and arterial phase hyperenhancement proportion (APHE) at MRI (HR, 1.77; P = .002). The ARMA model showed better predictive performance for ARFS compared with other staging systems and known risk factors (C-indexes, 0.72 vs 0.58-0.63; P value range, <.001-.003). High-risk patients (ARMA score ≥ 0.700) showed worse ARFS (P < .001) and recurrence-free survival (P = .002) than low-risk patients (ARMA score < 0.700). Conclusion The ARMA score, integrating periportal location, ablation duration, and APHE, predicted ARFS and identified patients at high risk for AR. Keywords: Model Training, Model Validation, Ablation Techniques, Liver, Outcomes Analysis, Aggressive Recurrrence, Microwave Ablation, Periportal Hepatocellular, Carcinoma, Arterial Phase Hyperenhancement Proportion, Ablation Duration Supplemental material is available for this article. © RSNA, 2026.
引用
- Wei R, Zuo M, Li W, et al. Risk Model for Predicting Aggressive Recurrence of Hepatocellular Carcinoma after Microwave Ablation Using MRI and Clinical Parameters. Radiol Imaging Cancer. 2026. PMID: 41575342. doi:10.1148/rycan.250304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。